The Phase 2 protocol explicitly allowed dose escalation delays and step-backs
Knowing about these side effects and how to manage them can help patients use semaglutide safely
The FDA's Pharmacy Compounding Advisory Committee is reviewing seven peptides for the 503A Bulks List
How do emerging regulations and innovative players change the landscape
Conflicts of Interest Eva Vilarrasa has received fees for consulting and/or as a speader and/or for travel and/or has participated in clinical trials sponsored by Abbvie, Almirall, Amgen, Boehringer Ingelheim, Bristol-Meyers Squibb, Celgene, Gebro, Isdin, Janssen, LEO Pharma, Lilly, Merck Serono, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi, and UCB